Genomic Guided Therapy With Dasatinib or Nilutamide in Metastatic Castration-Resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

August 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Nilutamide

Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.

DRUG

Dasatinib

Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.

Trial Locations (3)

27710

Duke University Medical Center, Durham

97239

Oregon Health and Science University, Portland

98109

University of Washington/Seattle Cancer Care Alliance, Seattle

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Duke University

OTHER